Displaying 85 (all) recruiting clinical trials.
-
PRESERVE Heart Study
Heart transplantation has long proven success for the treatment of end stage organ disease, and preservation of the heart prior to transplant remains an important ...Phase
Interventional
-
A PHASE 3 MULTI-CENTER RANDOMIZED DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO PLACEBO IN ADULTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial in participants with symptomatic nHCM. Approximately 420 eligible participants will be randomized in a 1 ...Phase
Interventional
-
A Stepped-Care Approach to Treating Dental Fear: A Sequential Multiple Assignment Randomized Trial for Cognitive-Behavioral Treatment via Mobile App and Evidence-Based Collaborative Care
A Sequential Multiple Assignment Randomized Treatment (SMART) design will be used to assess the effectiveness of a virtual stepped-care (progressive dosing) approach to dental fear ...Phase
Interventional
-
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and ...Phase
Interventional
-
A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
This is an international, multicenter, open-label, randomized, Phase 3 study in patients with TNBC who have received neoadjuvant chemotherapy with or without checkpoint inhibitor (CPI ...Phase
Interventional
-
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-METHYL-D-ASPARTIC ACID RECEPTOR (NMDAR) OR ANTI-LEUCINE-RICH GLIOMA-INACTIVATED 1 (LGI1) ENCEPHALITIS
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich ...Phase
Interventional
-
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective Randomized Trial
This safety study is a Phase 3, prospective, open-label, randomized (1:1 ratio), parallel group study of GTX-104 (nimodipine injection for IV infusion) compared with ...Phase
Interventional
-
Site for S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET) A RANDOMIZED PHASE III STUDY
Site for This is a randomized Phase III trial comparing a standard neoadjuvant chemotherapy regimen to an experimental neoadjuvant chemotherapy regimen that omits AC therapy ...Phase
Interventional
-
SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression =50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression
Study JZQB is a global, multicenter, randomized, double-blind, placebo-controlled, Phase 3 study that will enroll participants with unresectable, advanced or metastatic KRAS G12C-mutant NSCLC into ...Phase
Interventional
-
A Phase 3 Randomized Double-blind Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II IIIA IIIB (N2) Non-small Cell Lung Cancer
This clinical study will evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II to IIIB (N2 ...Phase
Interventional
